| scholarly article | Q13442814 |
| P2860 | cites work | Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome | Q46852534 |
| Esophagogastric varices as a prognostic factor for the determination of clinical stage in patients with primary biliary cirrhosis | Q47322110 | ||
| Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. | Q50694965 | ||
| Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. | Q50790143 | ||
| Optimal timing of liver transplantation for primary biliary cirrhosis. | Q52240035 | ||
| Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: predicting outcomes with natural history models. | Q52241867 | ||
| Living donor liver transplantation for primary biliary cirrhosis: retrospective analysis of 50 patients in a single center. | Q53671529 | ||
| Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. | Q54118475 | ||
| Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. | Q54316297 | ||
| Frequency of monosomy X in women with primary biliary cirrhosis. | Q55038191 | ||
| Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. | Q55041843 | ||
| EASL Clinical Practice Guidelines: management of cholestatic liver diseases. | Q55051951 | ||
| Primary biliary cirrhosis | Q56428273 | ||
| Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis | Q57004434 | ||
| Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis | Q58376775 | ||
| Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants | Q24633806 | ||
| Apotopes and the biliary specificity of primary biliary cirrhosis | Q24646460 | ||
| HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases | Q24679388 | ||
| Guidelines on the management of osteoporosis associated with chronic liver disease | Q24685899 | ||
| Comprehensive mapping of HLA-A0201-restricted CD8 T-cell epitopes on PDC-E2 in primary biliary cirrhosis | Q28210193 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Lysophosphatidic acid is a potential mediator of cholestatic pruritus | Q28285205 | ||
| Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis | Q28374434 | ||
| Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis | Q28943317 | ||
| Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis | Q29417041 | ||
| Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis | Q33214445 | ||
| The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus | Q33280833 | ||
| Liver biopsy in primary biliary cirrhosis: clinicopathological data and stage | Q33486098 | ||
| Incidence of cancer in primary biliary cirrhosis: the Mayo experience | Q33601440 | ||
| Genomic variants associated with primary biliary cirrhosis | Q33693726 | ||
| Familial primary biliary cirrhosis in Hiroshima | Q33707458 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis | Q34027799 | ||
| Management of primary biliary cirrhosis: from diagnosis to end-stage disease | Q34027995 | ||
| Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis | Q34066419 | ||
| Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis | Q34087671 | ||
| Primary biliary cirrhosis: a 2010 update | Q34106999 | ||
| Genetic and familial considerations of primary biliary cirrhosis | Q34150688 | ||
| Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? | Q34190802 | ||
| Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study | Q34197885 | ||
| Update on the genetics and genomics of PBC. | Q34209276 | ||
| Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium | Q34272356 | ||
| Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis | Q34377943 | ||
| Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis | Q34394186 | ||
| Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes | Q34445524 | ||
| Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients | Q34462959 | ||
| Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis | Q34474110 | ||
| Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials | Q34550505 | ||
| Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis | Q34594429 | ||
| Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years | Q34932835 | ||
| Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2 | Q35610980 | ||
| NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis | Q36238069 | ||
| Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology | Q36249669 | ||
| The natural history of PBC: has it changed? | Q36249680 | ||
| Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells | Q36376478 | ||
| A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation | Q36519145 | ||
| Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses | Q36801651 | ||
| Conventional therapy of Sjogren's syndrome | Q36997278 | ||
| Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value | Q37154299 | ||
| The consequences of apoptosis in autoimmunity | Q37177836 | ||
| Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? | Q37228810 | ||
| Risk factors and prediction of long-term outcome in primary biliary cirrhosis | Q37826609 | ||
| Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? | Q37867201 | ||
| Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals | Q39225838 | ||
| Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid | Q39293482 | ||
| Itch in primary biliary cirrhosis: a patients' perspective | Q39325404 | ||
| The molecular mechanism of cholestatic pruritus. | Q39521008 | ||
| Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity | Q39809553 | ||
| Fine specificity of T cells reactive to human PDC-E2 163-176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: implications for molecular mimicry and cross-recognition among mitochondrial autoantigens | Q40846384 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Natural history of early primary biliary cirrhosis | Q41234807 | ||
| Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis | Q41871213 | ||
| Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis | Q42473784 | ||
| Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study | Q42551010 | ||
| A prospective trial of colchicine for primary biliary cirrhosis | Q42659809 | ||
| Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation | Q43173563 | ||
| Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis | Q43214926 | ||
| Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines | Q43253298 | ||
| Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. | Q43466373 | ||
| Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis | Q43478375 | ||
| Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid | Q43483632 | ||
| Are transient environmental agents involved in the cause of primary biliary cirrhosis? Evidence from space-time clustering analysis | Q43488392 | ||
| Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center | Q43513105 | ||
| Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization | Q43575984 | ||
| Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis | Q43629448 | ||
| Effect of bezafibrate in primary biliary cirrhosis: a pilot study | Q43651284 | ||
| Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. | Q43734578 | ||
| Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? | Q43807982 | ||
| Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial | Q44110703 | ||
| Fenofibrate treatment in patients with primary biliary cirrhosis | Q44110727 | ||
| Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation | Q44169502 | ||
| Genetic factors of susceptibility and of severity in primary biliary cirrhosis. | Q44396311 | ||
| Simplified criteria for the diagnosis of autoimmune hepatitis | Q44425899 | ||
| Immunization with a Xenobiotic 6-Bromohexanoate Bovine Serum Albumin Conjugate Induces Antimitochondrial Antibodies | Q44432155 | ||
| Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis | Q44477965 | ||
| Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients | Q44617739 | ||
| Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis | Q44772320 | ||
| Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations | Q45010914 | ||
| Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? | Q45206678 | ||
| The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis | Q45247238 | ||
| Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. | Q45250878 | ||
| Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial | Q45309693 | ||
| IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis | Q46106529 | ||
| Characterization of antimitochondrial antibodies in health adults | Q46110088 | ||
| Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid | Q46126105 | ||
| Prognosis in primary biliary cirrhosis: model for decision making | Q46316848 | ||
| Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice | Q46607067 | ||
| Natural history of primary biliary cirrhosis | Q46608065 | ||
| The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study | Q46614923 | ||
| Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis | Q46745228 | ||
| Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis | Q46775425 | ||
| Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment | Q46795010 | ||
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | 71-90 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | Hepatology Research | Q15752035 |
| P1476 | title | Guidelines for the management of primary biliary cirrhosis | |
| P478 | volume | 44 |
| Q41307825 | Anti-mitochondrial M2 Antibodies Enhance the Risk of Supraventricular Arrhythmias in Patients with Elevated Hepatobiliary Enzyme Levels. |
| Q42319828 | Anti-mitochondrial autoantibodies-milestone or byway to primary biliary cholangitis? |
| Q30244056 | Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016. |
| Q91431676 | Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis |
| Q85345310 | Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA |
| Q50591717 | Changing Nomenclature for PBC from "Primary Biliary Cirrhosis" to "Primary Biliary Cholangitis". |
| Q50976613 | Comparison between real-time tissue elastography and vibration-controlled transient elastography for the assessment of liver fibrosis and disease progression in patients with primary biliary cholangitis. |
| Q38858980 | Finding the cure for primary biliary cholangitis - Still waiting |
| Q90601482 | Gastrointestinal Manifestations of Systemic Sclerosis |
| Q37642274 | Genetic Contribution to the Pathogenesis of Primary Biliary Cholangitis. |
| Q47827554 | Genetics and epigenetics in the pathogenesis of primary biliary cholangitis. |
| Q48205313 | Increased hepatic ABCA1 transporter is associated with hypercholesterolemia in a cholestatic rat model and primary biliary cholangitis patients |
| Q88380162 | Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study |
| Q38620686 | It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology |
| Q47787189 | Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome |
| Q91688388 | Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis |
| Q97692944 | Polymorphism at rs9264942 is associated with HLA-C expression and inflammatory bowel disease in the Japanese |
| Q55009231 | Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis. |
| Q55287849 | Speculation of the Time-Dependent Change of FIB4 Index in Patients with Nonalcoholic Fatty Liver Disease: A Retrospective Study. |
| Q38888501 | Surveillance rates for hepatocellular carcinoma among patients with cirrhosis, chronic hepatitis B, and chronic hepatitis C based on Japanese claims database |
| Q58722495 | Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis |
| Q100750305 | The albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC |
| Q92840168 | The pathological appearance of hyaline droplets in Kupffer cells is not specific to patients with autoimmune hepatitis |
| Q88017698 | The therapeutic effect of UDCA is a factor in determining the prognosis of primary biliary cirrhosis |
Search more.